Navigation Links
Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation

Hagens Berman suit claims company insiders knowingly misrepresented the

company to investors

SEATTLE, Jan. 18 /PRNewswire/ -- Hagens Berman Sobol Shapiro filed a proposed class-action lawsuit on behalf of CellCyte Genetics Corporation (OTC Bulletin Board: CCYG) shareholders alleging company executives knowingly misrepresented the company and chief executive officer Gary A. Reys' background, causing company stocks to be traded at artificially inflated prices.

The lawsuit filed in U.S. District Court in Seattle claims defendants violated sections of The Exchange Act of 1934 during the class period of April 6, 2007 until and including January 9, 2008.

The complaint alleges that Reys' background was called into question after published news reports called out alleged discrepancies relating to Reys' finance degree from the University of Washington, a CPA designation, ties to the Washington Society of Certified Public Accountants and a strong track record within the pharmaceutical industry.

According to the complaint, CellCyte not only made these statements to potential investors but also to the Securities and Exchange Commission (SEC). These published statements had the cause and effect of creating an unrealistically positive assessment of CellCyte's prospects for investors.

According to the complaint, when CellCyte began looking for investors it sent unsolicited faxes to investors in Germany. The fax contained a story about CellCyte and a handwritten note announcing that "This is the stock that's about to take off!"

Additional claims made to both U.S. and German investors included "CellCyte shares could be the chance of your lifetime to turn $10,000 into $4 million, maybe even $15 million!" In addition to money making promises Reys' background was also touted in promotional materials, the complaint states.

Suspicion of the company came to light in early December 2007 when The Seattle Times published an article about the company's skyrocketing stock value. According to The Seattle Times, "a wave of glossy brochures and spam faxes, touting CellCyte with lofty claims, has helped propel the company's total market value to more than $440 million."

The complaint claims soon after Reys' credibility came into question, CellCyte took some of his biography information off its Web site. Within days of the removal, company stock fell 55 percent to $2.20 a share. CellCyte traded at a high of $7.02 per share just days before.

The Complaint alleges that the Defendants violated Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated there under against all defendants and that Defendants Gary A. Reys, Ronald W. Berninger, Robert H. Harris, G. Brent Pierce and James L. Rapholz violated Section 20(a) of the Exchange Act.

If you invested in CellCyte during the outlined class period you may be eligible to join this suit and move to be a lead plaintiff. The deadline for moving is March 14, 2008. You can contact plaintiff's counsel, Reed Kathrein at 510-725-3000, or via e-mail at More information on this lawsuit is available at

About Hagens Berman Sobol Shapiro

Hagens Berman Sobol Shapiro is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation, one of the largest anti-trust settlements in history; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co-counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit


Reed Kathrein (510) 725-3000 Mark Firmani (206) 443-9357

Hagens Berman Sobol Shapiro Firmani + Associates Inc.

SOURCE Hagens Berman Sobol Shapiro
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hagens Berman Sobol Shapiro Investigating CellCyte
2. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
3. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
4. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
5. CryoCor Files Patent Infringement Lawsuits Against CryoCath
6. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
7. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
9. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
Post Your Comments:
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
(Date:11/25/2015)... 2015 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... fireside chat discussion at the Piper Jaffray 27th Annual ... The discussion is scheduled for Wednesday, December 2, at ... A replay will be available for 14 days after ... Julie NormartVP, Corporate Communications and Business Development , BrewLife(858) ...
(Date:11/24/2015)... 2015  Asia-Pacific (APAC) holds the third-largest share ... The trend of outsourcing to low-cost locations is ... volume share for the region in the short ... in the CRO industry will improve. ... ), finds that the market earned revenues ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/19/2015)... 19, 2015  Although some 350 companies are actively ... a few companies, according to Kalorama Information. These include Roche ... the market share of the 6.1 billion-dollar molecular testing ... Market for Molecular Diagnostic s .    ... still controlled by one company and only a handful ...
(Date:11/18/2015)... --> --> ... report titled  Gesture Recognition Market - Global Industry Analysis, ... to the report, the global gesture recognition market was valued at ... US$29.1 bn by 2021, at a CAGR of 20.3% ... dominated the global gesture recognition market in ...
Breaking Biology News(10 mins):